The Wealth Company Mid Cap Fund
The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. There is no assurance that the investment objective of the Scheme will be achieved.
Growthvine rating: 1/5 — ranked #32 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹9.68 (as of 2026-11-17) |
|---|
| AUM | ₹173 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Aparna Shanker |
|---|
| Exit load | 1% for redemption within 180 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −11.81% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Market cap allocation
| Large cap | 5.7% |
|---|
| Mid cap | 71.4% |
|---|
| Small cap | 22.9% |
|---|
Concentration
| Top 5 holdings | 21.1% |
|---|
| Top 10 holdings | 35.7% |
|---|
| Total holdings | 53 |
|---|
| Index overlap | 21.4% |
|---|
| Active share | 78.6% |
|---|
Top holdings
- GE Vernova T&D India Limited — 4.7%
- Dixon Technologies (India) Limited — 4.7%
- ITC Hotels Limited — 4.2%
- HDFC Bank Ltd. — 4.0%
- The Clearing Corporation of India Ltd. 02-NOV-2026 — 3.7%
- Balkrishna Industries Ltd. — 3.6%
- Crompton Greaves Consumer Electricals Limited — 3.2%
- Amber Enterprises India Limited — 3.1%
- ICICI Prudential Life Insurance Company Limited — 2.8%
- Endurance Technologies Limited — 2.8%
Top sectors
- Consumer Durables — 14.8%
- Automobile — 12.2%
- Pharma & Biotech — 8.4%
Calendar-year track record
No calendar-year history.